厚生労働科学研究費補助金

循環器疾患等総合研究事業

# 各種高脂血症治療薬の糖尿病性心血管病進展予防効果の
# 総合的検討に関する研究
# （臨床研究実施チームの整備）

平成 17 年度総括研究報告書

主任研究者　　井口昭久

平成 18 （2006） 年 3 月

# 目次


# Ⅰ．総括研究報告
各種高脂血症治療薬の糖尿病性心血管病進展予防効果の総合的検討


井口　昭久

厚生科学研究費補助金（循環器疾患等総合研究事業）総括研究報告書
各種高脂血症治療薬の糖尿病性心血管病進展予防効果の総合的検討（臨床研究実施チームの整備）
主任研究者　井口　昭久（名古屋大学医学部附属病院病院長、名古屋大学大学院医学系研究科老年科学）

研究要旨　各種高脂血症治療薬の糖尿病性心血管病進展予防効果と作用機序を検討する。全体研究としては、主任研究者として、代謝内分泌学,循環器学,老年学,臨床薬理学専門医14名,12施設,40関連病院からなる研究班を結成した。2)17年3月末までに自立している糖尿病患者(4014名),耐糖能異常者(306名),正常群(1112名),計5432名を登録した。3)　事務局として全登録患者を集計し、nested case control cohort試験として,虚血性心疾患発症,死亡/同入院,CVD,ASO発症総死亡をエンドポイントに検討し、初年度イベント発症率は部分集計(糖尿病2748例)では2.1%で,従来の高脂血症単独が対象の本邦の研究成績より高率であった。　4)また、そのうち名古屋大学にて糖尿病患者215例、名古屋地区関連病院で糖尿病426例を登録し、上記研究に主体的に参加した。初年度イベント発症率は、名古屋大学にて脳血管障害1.4%、虚血性心疾患2.8%、その他0.5%と高率であり、登録者が高齢（平均74歳、ADLは自立）である事が関与していると推測された。関連病院では、各々0.2%、0.9%。0.7%で有った（平均年齢63歳）　現在,　I)(本邦又は欧米の)血清脂質管理値達成によるイベント予防効果,II)高脂血症病態(メタボリック症候群,閉経等)による差異,III)脳血管障害への効果,IV)新規高脂血症薬の安全性と多面的作用、V)医療経済効果を検討している。VI)更に第3年度は糖尿病学会,循環器学会,老年医学会認定施設と動脈硬化学会評議員への診療実態調査,他研究との比較解析を事務局として、主体的に行っていく予定である。,VII)糖尿病合併高脂血症薬の使用基準提示を目標とする。7)個別項目は,高齢者総合機能評価,痴呆発症(脳白室病変等),薬剤トランスポーター変異等を検討する.

## A．研究目的

背景）本邦においては糖尿病罹患者が増加しており,高脂血症合併例の増加及び心血管合併症のリスクとしての大きさが注目されている。加齢そのものによっても高脂血症患者の頻度は増大する。糖尿病性心血管病変は耐糖能異常の段階から進行し,長期罹患者が増加している。糖尿病患者の死因としては心血管合併症によるものが最も多く予防法確立が急務である。一方、糖尿病合併高脂血症の治療効果は血糖降下療法を凌駕する可能性も欧米の大規模臨床試験で報告され、日本動脈硬化学会は糖尿病罹患者は血清LDL-Cholesterolの管理目標値をB３以上　120　mg/dl以下としている。さらに米国では100mg/dl以下と推奨している。さらに、スタチン製剤をはじめとする高脂血症薬には血管への直接作用がある可能性が報告されている。　複数の生活習慣病を合併する患者,心・脳血管障害合併者の増加に伴

う治療方策が必要となっている。本研究は代謝内分泌学,循環器学,老年学,臨床薬理学医により研究班を結成し、エビデンスに基づく高脂血症合併糖尿病心血管病予防指針策定を目標とする。当該研究では名古屋大学を中心とし、一部関連病院での症例もあわせて登録し経過をフォローし、全体研究の中心となるように努力した。

## B&C．研究方法と結果

対象は昨年度登録した、全国12ケ所,40関連病院の共同研究機関より,当初計画より多い**糖尿病罹患者**4014名と**耐糖能異常群**302名、正常血糖者1112名である。内、名古屋大学にて糖尿病患者215例、名古屋地区関連病院で糖尿病426例を登録し、上記研究に主体的に参加した。原則として外来通院者等の自立した成人であるが**高齢罹患者**,**自立した**心筋梗塞,脳梗塞罹患者も含め、特に名古屋大学では付属病院老年科

で自立した高齢者を多く含めた。全体のプロフィールは糖尿病群では平均年齢(64.5歳),男女比(1.12),HbA1C7.2%, TC 206.3,TG 144.1, HDL-C 55.5 mg/dlであった。一方、名古屋大学では平均年齢74.1歳(ADLは原則自立)、男女比0.78、HbA1C6.9%,TC209.1mg/dlであった（以下集計中）。名古屋地区関連病院で糖尿病426例を登録し他（平均年齢63歳）。当該年度より年齢階層別,性別, 薬剤別＜スタチン製剤(約84%),フィブラート製剤(9%)等＞、更に到達脂質濃度別(日本動脈硬化学会基準達成度, 総コレステロール値で32.2%)に各々分類しnested case control cohort studyとして評価検討を行っている。虚血性心血管病(心, 脳血管障害,ASO)発症,入院等をend pointとし, 一般所見,脂質等の冠危険因子治療経過を追う。75才以上の高齢者（登録時自立）は自立度の変化も評価する事とした。初年度イベント発症率は全体研究では、部分集計(糖尿病2748例)では2.1%で、従来の高脂血症単独が対象の本邦の研究成績より高率であった。 また、名古屋大学では、脳血管障害1.4%、虚血性心疾患2.8%、その他0.5%と高率であり、登録者が高齢である事が関与していると推測された。関連病院では、各々0.2%、0.9%。0.7%で有った。薬剤効果は現在解析中であるが、水溶性、従来型、ストロングスタチン間で高脂血症管理目標値達成率に変化なく, 医師間に糖尿病リスクの判断レベルの差異を認めた。研究班として以下の方向性を出す。心血管病発症に対し1）血清脂質管理値達成によるイベント予防効果− LDL100mg/dl(欧米)と120mg/dlの影響分析,2）高脂血症パターン分類に加え,metabolic症候群,閉経後,高齢者,家族性等の病因別分類による発症頻度,薬剤効果,3）脳血管障害予防効果,4）新規薬剤(ストロングスタチン)の安全性,脂質低下作用以外の多面的作用等を,統計解析により薬剤の直接,間接効果として求める。5）医療経済効果(病態,年齢,到達脂質値別)である。個別研究は, 血管内皮機能,TNFα,NO代謝物等のバイオマーカー,インスリン抵抗性,痴呆発症等との関係を検討し成果が出ている。安全管理モニター(名大鍋島, 浜医大中島両教授)の管理を頂いている。

（倫理面への配慮）

いずれの施設でも、研究対象者となる協力者に対してインフォームドコンセントを徹底し、協力者の利益が損なわれる事がないように十分に留意した。本研究は名古屋大学医学部附属病院をはじめ共同研究者が所属する施設の倫理委員会に申請,承認後に施行されている。被験者には同意を書面で頂き,いつでも取り消しが可能である事を明記し,認知機能障害のある方は対象外としている。プライバシーは匿名化を行い個人名が特定化されないよう細心の注意をはかっている。

## D&E. 考察と結論

本研究の意義は具体的な糖尿病、高脂血症の治療指針の策定にあるが、更に、長寿社会,日本で増加する生活習慣病自体の合併、心及び脳血管障害合併者の診療、二次予防は、総合診療学、老年科学の領域でも重要と考え、代謝内分泌学、循環器学、老年学、臨床薬理学の専門家により,研究班を結成した。具体的な成果及び今後の発展は全体研究では、 1）糖尿病患者の重症度別評価に加え、高脂血症患者はメタボリック症候群罹患者,前期高齢者,閉経後女性（閉経後脂質上昇）等の層別の、目標脂質濃度、推奨薬剤を設定できる可能性を探る。当該研究で明らかになりつつ有るのは、糖尿病罹患者の血糖コントロールは高齢者ではむしろ良好に推移している（加齢による腎機能低下の影響か）点であり、血清脂質コントロールの意義がイベント数の現れる可能性がある。Nested case control cohort という手段をとり、全体の症例数を 4000 まで増やした事で、イベントに対する各種高脂血症薬の単独作用と、脂質低下作用におうところを直接, 間接作用として解析できる可能性が示唆されている。一方, 実態としては欧米はおろか本邦の学会ガイドラインでさえ 4 0％以下の準拠率である事が判明し、第 2 年度の班会議申し合わせが実行されればクロスオーバー試験的な作用が第 3 年度に期待される可能性もある。特に糖尿病合併高脂血症患者の心脳血管イベント発症率は部分集計では 2.1％強に上り, 特に名古屋

大学では4.7％と高率で、昨年末報告された
MEGA,JELISの約0.5％に比し,リスクの大きさ,逆
に言えば制御する必要性が示唆される。個別報告に
も有るようにスーパースタチンは単剤でも目標値
達成の可能性があるが，部分集計では50％前後に
留まった。適応症例がかなり重症高脂血症患者に偏
っている可能性も示唆される。２）脳血管障害は,
脂溶性スタチンにのみ効果を認める可能性があり
検討している。３）第２年度は、医療経済学者、疫
学統計学者を班員に加えたため上記にみとめられ
る解析法が選択された。また医療経済学的には
MEGA studyと当該研究の医療経済効果の比較を
お願いしている。4)第３年度は各エンドポイントを
中心に本格的解析を進める予定で、年々市場規模が
増大している高脂血症薬の効果的,効率的な投与方
法を提言したい。個別研究では高齢者の自立度及び
QOL改善に対する高脂血症薬治療の有効性の可能
性を探りたい。バイオマーカーの分析により、高リ
スク群のスクリーニング及び治療効果の判定に応
用したい。高脂血症薬の作用機序として、脂質低下
作用に加え、NO利用化による血管内皮機能改善を
直接的抗動脈硬化作用の一つとして推測しており、
広義の分子標的治療薬としての可能性やテロメラ
ーゼ等、老化関連酵素への関与の可能性も探りたい。
全体研究は同質の研究を企図して限定された施設
で遂行しているため、06年度は、もう一つの全体
研究として全国1500の糖尿病学会,循環器学会,老
年医学会認定施設と約400名の動脈硬化学会評議
員への診療実態調査により各専門医（施設）の診療
方針の実態を明らかにする計画を持つ。第３年度
（2006年度）末には中間解析を行い,糖尿病合併時
の高脂血症薬の作用機序を臨床面から提示し,エビ
デンスに基づく診療指針を患者層別、薬剤別に具体
的に明らかにすべく研究を発展させたい。

## F． 健康危険情報
現在のところは認めない。

## G． 研究発表
（１） 論文発表
1:Ding Qungfang, Hayashi T, Matsui-Hirai H, Miyazaki A,

Fukatsu A, Iguchi A, Ignarro LJ. Risks of CHD identified by different criteria of metabolic snydrome and related changes of adipocytokines in elderly post menopausal women. J Diabetes and its Complication (in press)

2: Hayashi T, Matsui-Hirai H, Packiasamy AR, Kano-Hayashi H, Iguchi A.他２名 Selective iNOS inhibitor, ONO1714 successfully retards the development of high-cholesterol diet induced atherosclerosis by novel mechanism. Atherosclerosis (in press)

3: Hayashi T, Juliet PA, Matsui-Hirai H, Miyazaki A, Fukatsu A, Funami J, Iguchi A, Ignarro LJ. l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits. Proc Natl Acad Sci U S A. 2005;102:13681-13686.

4: Hayashi T, Nomura H, Esaki T, Hattori A, Kano-Hayashi H, Iguchi A. The treadmill exercise-tolerance test is useful for the prediction and prevention of ischemic coronary events in elderly diabetics. J Diabetes Complications. 2005;19:264-268.

5: Hayashi T, Juliet PA, Kano-Hayashi H, Tsunekawa T, Dingqunfang D, Sumi D, Matsui-Hirai H, Fukatsu A, Iguchi A. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes Metab. 2005;7:334-43.

6:.Sun Y, Hayashi T, . Kumagai Y. et al. 2,4,6-Trinitrotoluene inhibits endothelial nitric oxide synthase activity and elevates blood pressure in rats. Arch Toxicol. 2005; 16:1-6

7. Nomura H, Hayashi H, Hayashi T., Endo H, Miura H, Satake S, Iguchi A "Bowel incontinence is related to improvement in basic activities of daily living (BADL) in residents of long-term care health facilities for the elderly in Japan". Geriatrics Gerontology International. 2005; 5:48-52

和文総説

1 林 登志雄 女性における心血管疾患の病態と特徴 血管疾患 Cardiac Practice 16 361-366 2005

2 林 登志雄 井口昭久 エストロゲン欠乏による血管、内分泌疾患と治療 女性ホルモン Up to Date 性差と医療 3、P181-187 2006

3 林 登志雄 高脂血症-高齢患者の薬物治療—Medicament News, 1861 P4-7, 2006

4 林登志雄,井口昭久 動脈硬化症の性差—女性ホルモンの作用を中心に 総合臨床 55 P292-298 2006

（２） 学会発表
＜国際学会＞
#Annual Congress of the European Society of Cardiology 3-7 September Stockholm Sweden
1) Nomura H, Hayashi T, Osawa M, Iguchi A.
BNP is a useful marker of latent cardiac failure in elderly, however IL-6 and TNFα are more important in bed ridden and NO in renal failure.
2) Hayashi T, Miyazaki-Akita A, Iguchi A. Estrogen improves the eNOS dysfunction in hyperglycemia-Implication for anti-atherosclerotic effect of estrogen in diabetes.
＜シンポジウム等＞
# 第 37 回日本動脈硬化学会 7 月 14-15 日 東京
コントロバーシー 1 女性の高脂血症
林 登志雄 女性の高脂血症 これからの薬物治療のあり方
# 第 13 回創薬フォーラム 9 月 8 日 東京
シンポジウム「血管内皮機能障害と創薬- NO と $O_2$ をめぐって」

林 登志雄 「エストロゲンの血管内皮機能保護作用について」
＜一般演題＞
# 第 69 回日本循環器学会学術集会 3 月 27-29 日 東京
Featured Research Session
1)Hayashi T, Osawa M, Iguchi A. Estrogen improves the eNOS dysfunction in Hyperglycemia-Implication for Anti-atherosclerotic Effect of Estrogne in Diabetes The high incidence of ischemic coronary lesion in elderly diabetics and the efficient prediction by the exercise tolerance test.
2)Hayashi T, Osawa M, Iguchi A. The Effect and Meaning of Estrogen on Telomerase Activity in Cultured Endothelial Cells-Implication of Effect of Aging on Atherosclerosis.
3)Kishimoto N, Sakuma I, Kano H, Osawa M, Nagai K, Sohma T, Hayashi T, Iguchi A, Tsutsui H. Simvastatin Improves Endothelial Function Due to Its Effects on Lipids and Pleiotropic Effects in Patients with Chronic Hemodialysis
# 第 42 回日本老年医学会学術集会 6 月 16-18 日東京
１） 大澤雅子、林登志雄、井口昭久 ニトログリセリン耐性における NO と活性酸素のクロストーク
２） 林 登志雄, 大澤雅子、井口昭久 １７b エストラジオールは高血糖による内皮由来 NO 合成酵素の機能異常を改善する—女性ホルモンの抗動脈硬化作用としての可能性
３） 大澤雅子、林登志雄、井口昭久 高齢者総合機能評価—特に自立度の決定評価因子の検討—血中バイオマーカーの関係について

## H．知的財産権の出願、登録状況
特になし

臨床研究実施チームの組織

（1）臨床研究実施チーム（a組）

| | ①若手医師及び臨床研究協力者に対する指導者 | ②若手医師 | ③臨床研究協力者 |
|---|---|---|---|
| 氏　　　　名 | 林　登志雄 | 大澤　雅子 | 平井　寿子 |
| 分担する研究項目 | 診療,同意取得、検査,群分け処方 | 診療,同意取得検査,データ解析 | 検査、データ解析 |
| 最終卒業学校・卒業年次・学位及び専攻科目 | 信州大学医学部医学科昭和59年卒・医学博士・老年科学 | 岐阜大学医学部医学科平成10年卒・医学士・老年科学 | 岐阜大学農学部生命科学科修士平成10年卒・農学修士・老年科学 |

Diabetes
AND ITS
Complications

ELSEVIER

# The treadmill exercise-tolerance test is useful for the prediction and prevention of ischemic coronary events in elderly diabetics

Toshio Hayashi*, Hideki Nomura, Teiji Esaki, Ayako Hattori,
Hatsuyo Kano-Hayashi, Akihisa Iguchi

*Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan*

## Abstract

**Background:** Approximately 80% of cases of ischemic heart disease (IHD) occur in patients with nonstenotic coronary arteries, and few studies have systematically assessed exercise testing (TMT) as a predictor of risk in the elderly. **Methods:** TMT was carried out using a protocol for the independent and active elderly ($n=176$). After $4.1\pm0.5$ years follow-up, logistic regression analysis was performed for each coronary risk factor such as diabetes mellitus (DM) and hypercholesterolemia (HC). According to the results, patients were divided into Gp HC, hypercholesterolemic patients; Gp DM, diabetics; Gp HC+DM, hypercholesterolemic diabetics; and Gp C, nonhyperlipidemic and nondiabetics. Sensitivity and specificity of TMT for IHD (significant stenosis or acute coronary syndrome) were analyzed. **Results:** Odds ratios for each risk factors are as follows: DM, 4.167; HC, 4.485; and DM+HC, 8.652. Notably, TMT was 17.59. Age was a significant risk, but hypertension was not. Positive ischemic signs in TMT were observed in 52.7%, 28.6%, 33.3%, and 16.3% in the Gp HC+DM, HC, DM, and C groups, respectively. Only three participants complained of chest pain during the TMT. Significant stenosis was observed in 75.0%, 71.4%, 69.2%, and 60.0% of coronary angiography (CAG)-receiving patients of Gp HC, DM, HC+DM, and C. During the observation term, acute coronary syndromes occurred in 4.7%, 3.3%, 5.5%, and 0% of patients in the Gp HC, DM, HC+DM, and C groups, respectively. The sensitivity of TMT for IHD was higher than 66.7% and specificity was higher than 94.1% in each group. **Conclusion:** An exercise tolerance test in the elderly, especially for diabetics and hypercholesterolemic patients, is useful for the diagnosis of IHD.
© 2005 Elsevier Inc. All rights reserved.

## 1. Introduction

Recent mega-trials have revealed that strict control of complicated coronary risk factors such as hyperlipidemia is important for the prevention of diabetic vascular lesions (Jonsson, Cook, & Pedersen, 1999). Exercise stress testing is an accepted means of estimating and diagnosing cardiovascular disease, as well as of predicting cardiovascular and all-cause mortality (Gianrossi, Detrano, Mulvihill, et al., 1989). However, approximately 80% of cases of ischemic heart disease (IHD) occur in patients with nonstenotic coronary arteries, and these cases cannot be predicted by an exercise-tolerance test (Bezerra, Higuchi,

Libby, Ramires, et al., 2001). Furthermore, few studies have systematically assessed exercise testing as a predictor of risk in the elderly. Diabetic coronary lesions are known to have long segmental narrowing, and the incidence of IHD seems to be especially increased in patients who have had diabetes for more than 10 years (Al-Attar, Mahussain, & Sadanandan, 2002; Stein, Weintraub, Gebhart, et al., 1995). We have speculated that an exercise-tolerance test would be useful for the evaluation and prevention of IHD in elderly diabetics, if it could be carried out in a safe manner. We therefore modified the protocol of the exercise burden for the treadmill exercise-tolerance test (TMT) to make it more suitable for elderly patients.

The present study focused on the relationship between the frequency of cardiovascular ischemia, the exercise-tolerance test, and coronary risk factors in the elderly.

---

* Corresponding author. Tel.: +81 52 744 2364; fax: +81 52 744 2371.
*E-mail address:* hayashi@med.nagoya-u.ac.jp (T. Hayashi).

## 2. Research design and method

### 2.1. Patient selection

Between April 1997 and March 2000, 342 patients were enrolled in this study. All patients were ambulatory and were either referred to our geriatric clinic (Nagoya University Hospital) or enrolled in our hospital to receive educational hospitalization for diabetes. Among them, 176 patients who were older than 65 years and who underwent an exercise-tolerance treadmill test were prospectively enrolled and followed for $4.1\pm0.5$ years (Table 1). All patients gave their informed consent to participate in this study. None of the patients had experienced a myocardial infarction in the 3 months prior to enrollment, and they were independently active in daily life, as determined by their Lawton and Berthal scores (Collin, Wade, Davies, & Horne, 1988; Lawton & Brody, 1969).

### 2.2. Protocol and method

TMT was performed according to a protocol for the elderly, which we adapted from a protocol used for veterans in the United States (Prakash, Myers, & Froelicher, 2001). We changed the test so that each step lasted 2 min due to the age-related limitation of exercise tolerance (Hagberg, 1994; Tamesis et al., 1993; Table 2). The chronotropic response to exercise was assessed by estimating the proportion of the heart-rate reserve (220-age) used at peak exercise (Lauer, Francis, Okin, et al., 1999). Ischemic changes in the treadmill test were diagnosed using the Minnesota protocol; in brief, 1.0 mm or more ST segment elevation or depression in two or more leads was identified as positive. Exercise tolerance was estimated as METS, which was calculated from the participant's TMT results, body weight, age, and estimated Vo2 at rest. Plasma lipid and glucose levels were also measured. The diagnosis of hypercholesterolemia (HC) and diabetes followed the guidelines of the American Heart Association and Diabetes Association (Krauss, Eckel, Howard, et al., 2000; Resnick, Harris, Brock, et al., 2000). This study was approved by our institutional review board.

### 2.3. Follow-up data/definition of adverse outcome

All patients were followed until April 2002, with the mean follow-up period being $4.1\pm0.5$ years after the treadmill test. The outcome was determined from patient

Table 1
Profile of patients

| Patients number | 147 (Male 71, Female 76) |
| --- | --- |
| Age (years) | 71.7+0.4 |
| Hypercholesterolemia | 78 (Male 38, Female 40) |
| Diabetes mellitus (DM) | 66 (Male 32, Female 34) |
| Hypertension | 78 (Male 40, Female 38) |
| [Hypercholesterolemia+DM] | [36 (Male 17, Female 19)] |

Table 2
Protocol of treadmill test for elderly

| Stage | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Period (min) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Speed (miles/h) | 1 | 2 | 2 | 2 | 2 | 2 | 2.5 | 3.3 | 3.3 |
| Gradient (%) | 0 | 0 | 5 | 10 | 15 | 20 | 20 | 20 | 25 |
| METs | 2.5 | 3 | 5 | 6 | 8 | 9 | 10 | 11 | 13 |

interviews, hospital chart reviews, and telephone interviews. An adverse outcome was defined as the finding of significant stenosis in coronary angiography (CAG) with or without coronary intervention, such as percutaneous coronary angioplasty or ischemic cardiac events in the follow-up term. Cardiac events were defined as cardiac death, nonfatal MI, and resuscitated ventricular fibrillation or tachycardia after the TMT. Only the most severe outcome was considered an endpoint. Twenty-nine patients were excluded because of patient or physician refusal to follow-up ($n=13$), an inability to repeat the exercise treadmill test safely due to hearing loss ($n=2$), or geographic relocation ($n=14$). A total of 147 elderly individuals could be followed, and data on their histories of ischemic coronary disease, results of CAG, medication, and other parameters were recorded (Table 1). Based on the odds ratios evaluated as described below, patients older than 65 years were divided into four groups: Gp HC, hypercholesterolemic patients ($n=42$); Gp diabetes mellitus (DM), diabetic patients ($n=30$); Gp HC+DM, hypercholesterolemic and diabetic patients ($n=36$); and Gp C, nondiabetic and nonhyperlipidemic patients ($n=39$).

### 2.4. Statistical analysis

Continuous data were expressed as the means±S.D. Categorical variables were analyzed by the chi-square test or Fisher's Exact Test. Continuous variables within groups were analyzed by repeated measures using analysis of variance (ANOVA). The Student's $t$ test was used to identify significant differences in means. Stepwise multiple logistic regression analyses were used to identify the independent predictors of outcome, as well as the additive prognostic values of the clinical data and the exercise treadmill test. Fisher's Exact Test was used to calculate odds ratios or the probability of detecting any variables included in the logistic regression analysis in patients with adverse outcomes relative to patients with good outcomes.

## 3. Results

The odds ratios of each risk factor as determined by logistic regression analysis are shown in Table 2. Briefly, the odds ratios were as follows: DM, 4.167; HC, 4.485; and DM+HC, 8.652 ($P<.01$, respectively). That of age was significantly high (2.953; $P<.05$), whereas that of hypertension was not significant (2.151; $P=.053$). Notably, the odds ratio for positive ischemic signs as evaluated by TMT was 17.59.

Table 3
Odds ratio and 95% CI of each risk factor by logistic regression analysis

| Hypercholesterolemia | 4.485* (1.495–12.28) |
|---|---|
| DM | 4.167* (1.477–10.81) |
| DM+Hypercholesterolemia | 8.652* (2.543–13.68) |
| Hypertension | 2.151 (0.845–9.26) |
| Age | 2.953** (0.985–10.36) |
| Positive finding in TMTest | 17.590*** (6.77–47.02) |

\* $P<.01$.
\*\* $P<.05$.
\*\*\* $P<.001$.

We therefore divided the patients into four groups (Table 3): Gp HC, hypercholesterolemic patients ($n=42$; $72.0\pm0.5$ years old; LDL-C, $150.7\pm10.4$ mg/dl; exercise tolerance, $6.4\pm0.2$ METs); Gp DM, diabetic patients ($n=30$; $72.3\pm0.9$ years old; HbA1C, $7.6\pm0.5$ g/dl; disease duration, $12.0\pm1.2$ years; $6.0\pm0.5$ METs); Gp HC+DM, hypercholesterolemic and diabetic patients ($n=36$; $71.4\pm0.8$ years old; LDL-C, $149.5\pm11.5$ mg/dl; HbA1C, $7.0\pm0.3$ g/dl; disease duration for diabetes, $12.9\pm1.1$ years; $6.4\pm0.3$ METs); and Gp C, nondiabetic and nonhypercholesterolemic patients ($n=39$; $71.6\pm0.9$ years old; $6.2\pm0.4$ METs). The mean age and the frequency of other coronary risk factor complications, such as hypertension, smoking, and others, were not significantly different among the four groups. The TMT-positive ratios were 28.6%, 33.3%, 52.7%, and 16.3% in participants from the Gp HC, DM, HC+DM, and C groups, respectively (Fig. 1). Only three participants complained of chest pain during the TMT test

(two in Gp HC+DM and one in Gp HC), and all of them became symptom-free within 5 min after exercise; all other positive patients were symptom-free. The ratios of patients receiving CAG per TMT-positive patient within 8 months after TMT were 66.7%, 63.6%, 68.4%, and 62.5% in the Gp HC, DM, HC+DM and C groups, respectively. CAG was not done for the following reasons: (1) patient refusal, lack of understanding of the CAG, and/or coronary intervention due to risk ($n=11$); (2) a high risk of coronary intervention for other general diseases such as chronic renal failure or cerebral infarction ($n=6$); and (3) physician refusal due to the risk of coronary intervention or CAG because of cognitive impairment, and others ($n=6$). In some patients who did not receive CAG but were suspected to have stenotic lesion by other examinations, medication such as anti-platelets and/or NO donors, such as isosorbide dinitrate, was prescribed. More than 75% stenosis was observed in 75.0%, 71.4%, 69.2%, and 60.0% of CAG-receiving patients of the Gp HC, DM, HC+DM, and C groups, respectively, and coronary intervention was performed in all of these cases (Fig. 1). During the $4.1\pm0.5$ years of observation, ischemic coronary diseases such as angina pectoris or acute myocardial infarction occurred in 4.7% (8.3), 3.3% (10.0), 5.5% (5.3), and 0% of patients in the Gp HC, DM, HC+DM, and C groups, respectively (the percentage for TMT-positive patients). Older patients (older than 75 years of age) had more events (7.3% vs. 0%) than did the relatively younger patients (65–74 years; $P<.001$). Cardiac death was significantly more frequent in older



Fig. 1. Left: The frequency of TMT-positive findings and the corresponding treatments chosen for each disease group. Gp HC: hyper-cholesterolemic patients ($n=42$); Gp DM: diabetic patients ($n=30$); Gp HC+DM: hypercholesterolemic and diabetic patients ($n=36$); Gp C: nondiabetic and nonhypercholesterolemic patients ($n=39$). Right: The frequency of TMT-negative findings and the corresponding treatments chosen for each disease group.

Table 4

Patients profile who have coronary stenosis by CAG study, acute coronary syndrome, or drug treatment without CAG

| | Percentage (%) of possible IHD | | | Sensitivity of TMT for IHD | Specificity of TMT for IHD |
|---|---|---|---|---|---|
| | Total | In TMT-positive patients | In TMT-negative patients | | |
| Gp HC (42) | 23.2 | 75.0 | 5.6 | 72.7≦ | 96.7 |
| Gp DM (30) | 26.7 | 72.7 | 0 | 66.7≦ | 100 |
| Gp HC+DM (36) | 41.7 | 73.7 | 5.9 | 68.8≦ | 94.1 |
| Gp C (39) | 10.3 | 66.7 | 0 | 66.7≦ | 100 |

Possible IHD means significant stenosis, ACS, and drug treatment during the observation term (4.1±0.5 years).

Sensitivity is calculated by (ACS and significant stenosis)/(TMT-positive patients–patients treated by drug without CAG).

Specificity is calculated by (no ACS or no significant stenosis)/(TMT-negative patients).

patients ($P<.001$). Finally, significant stenosis observed by CAG, IHD, or medical intervention during follow-up term was observed in 75.0%, 72.7%, 73.7%, and 66.7% of TMT-positive patients in the Gp HC, DM, HC+DM, and C groups, respectively. Sensitivity and specificity were calculated as shown in Table 4, and they mean the reliability and usefulness of TMT for the diagnosis or speculation of IHD.

## 4. Discussion

The elderly population is increasing all over the world, and Japan is now the world's most aged society. Elderly individuals with IHD have higher rates of physical disability, as defined by a diminished ability to perform the activities of daily living, than do persons without IHD. Older age and clinical manifestations of angina pectoris or chronic heart failure are known to be associated with the highest rates of disability (Morey, Pieper, Crowley, Sullivan, & Puglisi, 2002). The odds ratio for age was also found to be significantly high in the present study (2.953; $P<.05$).

TMT using a protocol for the elderly was shown in the present study to be safe and possibly useful for maintaining independent activities of daily living in the elderly, as the positive ischemic signs evaluated by TMT showed an odds ratio of 17.59 despite the fact that 90% of patients testing positive were asymptomatic. The exercise tolerance (mean=6.1±0.5 METs) determined in the present study indicates that the elderly have the capacity to maintain the activities of daily living, including voidance and using the stairs. The optimal test duration is from 8 to 12 min, and the protocol workloads should be adjusted to permit this duration (Myers & Froelicher, 1993).

The odds ratios for each risk factor, as determined by logistic regression analysis, were the following: DM, 4.167; HC, 4.485; and DM+HC, 8.652 ($P<.01$, respectively). Hypertension, however, was not found to be significant (2.151; $P=.053$). Although the importance of diabetes as a coronary risk factor is well known, almost all patients with a positive TMT test were asymptomatic and showed a relatively high percentage of coronary stenosis. TMT is useful in screening for diabetic coronary macroangiopathy. The frequency of the TMT-positive ratio

was found to be relatively high in the present study; we speculate that this finding was due to the fact that the study participants had suffered from diabetes for long periods and to our adoption of the standards of the AHA exercise-tolerance test (Gibbons, Balady, Basley, et al., 1997). We also examined 166 patients younger than 65 years as young control participants; these patients underwent TMT using a symptom-limited modified Bruce protocol and were followed for 4.0±0.8 years (data not shown). Their positive ratios were less than 15%, even in the patients with diabetes complicated with hyperlipidemia (data not shown). Despite a paucity of data on the predictive value of stress tests in older populations, current stress-testing guidelines extend the following recommendations to all adults aged 65 and older (Gibbons et al., 1997). The value of exercise training in patients older than 65 years is supported by a recent study involving 772 men with coronary heart disease, in which physical activity (walking, in particular) for a total of at least 4 hours per week was associated with a significant reduction in overall mortality. Thus, TMT should be useful in cardiac-rehabilitation programs for the elderly. Regarding the interpretation of these findings, a number of limitations should be mentioned. Goyara, Jacobsen, Pellikka, et al. (2000) found that exercise capacity, but not ST-segment changes, was predictive of mortality and cardiovascular events, but they did not distinguish patients who were older than 75 years of age from those who were younger. These findings do not agree with those of the present study, although we cannot identify the reason for this discrepancy. In our study, some patients did not undergo CAG due to patient or physician refusal, and others. Although the risk associated with CAG is small, some physicians cannot justify it fully to patients. This study was also confined to those patients who were referred for exercise testing and thus were able to walk on a treadmill. Despite these facts, our results demonstrated conclusively that TMT was useful for the prevention and management of ischemic coronary artery disease in elderly patients, especially in those with diabetes.

Especially, the high value of specificity of TMT means that TMT-negative finding means the less possibility of IHD and that TMT can be used as screening test of IHD for independent elderly.

# References

Al-Attar, A. T., Mahussain, S. A., & Sadanandan, S. (2002). Cardiac tests in asymptomatic type 2 diabetics. *Medical Principles and Practice, 11*, 171–175.

Bezerra, H. G., Higuchi, M. L., Libby, P., Ramires, J. A., et al. (2001). Atheromas that cause fatal thrombosis is usually large and is frequently accompanied by vessel enlargement. *Cardiovascular Pathology, 10*, 189–196.

Collin, C., Wade, D. T., Davies, S., & Horne, V. (1988). The Barthel ADL Index: A reliability study. *International Disability Studies, 10*, 61–63.

Gianrossi, R., Detrano, R., Mulvihill, D., et al. (1989). Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. *Circulation, 80*, 87–98.

Gibbons, R. J., Balady, G. J., Basley, J. W., et al. (1997). ACC/AHA guidelines for exercise testing: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). *Circulation, 96*, 345–354.

Goyara, T. Y., Jacobsen, S. J., Pellikka, P. A., et al. (2000). Prognostic value of treadmill exercise testing in elderly persons. *Annals of Internal Medicine, 132*, 862–870.

Hagberg, J. M. (1994). Exercise assessment of arthritic and elderly individuals. *Bailliere's Clinical Rheumatology, 8*, 29–52.

Jonsson, B., Cook, J. R., & Pedersen, T. R. (1999). The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. *Diabetologia, 42*, 1293–1301.

Krauss, R. M., Eckel, R. H., Howard, B., et al. (2000). AHA dietary guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation, 102*, 2284–2299.

Lauer, M. S., Francis, G. S., Okin, P. M., et al. (1999). Impaired chronotropic response to exercise stress testing as a predictor of mortality. *Journal of the American Medical Association, 281*, 524–529.

Lawton, M. P., & Brody, E. M. (1969). Assessment of older people: Self-maintaining and instrumental activities of daily living. *Gerontologist, 9*, 179–186.

Morey, M. C., Pieper, C. F., Crowley, G. M., Sullivan, R. J., & Puglisi, C. M. (2002). Exercise adherence and 10-year mortality in chronically ill older adults. *Journal of the American Geriatrics Society, 50*, 1929–1933.

Myers, J., & Froelicher, V. F. (1993). Exercise testing. Procedures and implementation. *Cardiologia Clinica, 11*, 199–213

Prakash, M., Myers, J., & Froelicher, V. F. (2001). Diagnostic exercise tests on 4000 consecutive men. *American Heart Journal, 142*, 127–135.

Resnick, H. E., Harris, M. I., Brock, D. B., et al. (2000). American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: Results from the third national health and nutrition examination survey. *Diabetes Care, 23*, 176–180.

Stein, B., Weintraub, W. S., Gebhart, S. P., et al. (1995). Influence of diabetes mellitus on early and late outcomes after percutaneous transluminal coronary angioplasty. *Circulation, 91*, 979–989.

Tamesis, B., Stelken, A., Byers, S., Shaw, L., Younis, L., Miller, D. D., & Chaitman, B. R. (1993). Comparison of the asymptomatic cardiac ischemia pilot and modified asymptomatic cardiac ischemia pilot versus Bruce and Cornell exercise protocols. *American Journal of Cardiology, 1972*, 715–720.

# Risks of CHD Identified by Different Criteria of Metabolic Syndrome and Related Changes of Adipocytokines in Elderly Post Menopausal Women

Qun-Fang Ding , Toshio Hayashi MD, PHD ⋆, Masako Osawa, Hisako Hirai Iguchi, Akihisa MD, PHD1

Department of Geriatrics, Medicine in Growth and Aging, Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Corresponding author: Toshio Hayashi MD, PHD

TEL: +81-52-744-2364, Fax : +81-52-744-2371, Email address: hayashi@med.nagoya-u.ac.jp

Address of correspondence: Department of Geriatrics, Nagoya University Graduate School of Medicine 65 Tsurumai-Cho, Showa-Ku, Nagoya 466-8550 JAPAN

Abstract

The subject of this study was to assess the capacity of different criteria of metabolic syndrome (MetS) to identify risks of coronary heart diseases (CHD) and related changes of adipocytokines in post menopause women. A cross-sectional study was carried out in 225 community dwelled, elderly post menopause Chinese women without hormone replacement therapy (HRT). Blood pressure (BP), body mass index (BMI), serum lipid profiles, fasting glucose were analyzed and insulin sensitivity was estimated by homeostasis model assessment (HOMA-IR). Serum tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), and adiponectin were measured simultaneously. Prevalence of MetS identified by Third Report of the National Cholesterol Education Programme Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(NCEP-ATPIII), International Diabetes Federation(IDF), Chinese Diabetes Society(CDS), and Japanese Society of Internal Medicine (JPN) were 27.31%, 37.34%, 23.29%, and 13.65%, respectively. No significant differences of baseline data were found among different MetS groups, except a significant higher waist circumference of JPN MetS group than other MetS groups. The prevalence of confirmed CHD in the four MetS groups were 26.2%, 18.6%, 26.9%, and 32%, respectively. Odds Ratios for CHD were 1.905(95% CI 1.273-2.851), 1.208 (95% CI 0.778-1.876), 1.997(95% CI 1.238-3.221), and 2.336(95% CI 1.119-4.876), respectively. JPN-MetS group had higher levels of TNF alpha and interleukin-6, whereas CDS-MetS group correlated better with lower adiponectin levels. Conclusion: IDF definition for MS is the most sensitive one to metabolic disorders, whereas JPN and CDS definitions correlate better with CHD and changes of adipocytokines.

Key words    Metabolic syndrome; Cardiovascular diseases; Adipocytokines.

## 1. Introduction

Metabolic syndrome (MetS) is a cluster of metabolic disorders which has been convinced to be a strong predictor of diabetes mellitus (DM) and cardiovascular diseases (CVD) (Wilson et al, 2005). The first criteria was published by World Health Organization (WHO) in 1998 ( Alberti, Zimmet for the World Health Organization, 1998), and then by the Third Report of the National Cholesterol Education Programme Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATPIII) in 2001(Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001), and International Diabetes Federation (IDF) in 2005 (International Diabetes Federation, 2005). Comparing with NCEP ATPIII definition, IDF definition gives more weight to central obesity by taking it as the precondition of MetS diagnosis. Although the IDF definition has already considered of the ethnic characteristics of Asian by defining central obesity with lower levels of waist circumferences, it is still different from criteria published by Chinese Diabetes Society (CDS) (Chinese Diabetes Society, 2004) and Japanese Society of Internal Medicine (JPN) (Matuzawa et al., 2005) for their own populations.

Visceral adipose tissue plays an important role in the accumulation of metabolic disorders and chronic inflammations related to MetS by secreting adipocytokines, such as tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), prothrombin activator inhibitor-1 (PAI-1), and adiponectin. Adiponectin has been proved to play an unique role by its anti-atherogenic and insulin sensitizing properties (Lihn , Pedersen  & Richelsen , 2005, Goldstein, Scalia, 2004 ). Lower adiponectin levels are associated with obesity and insulin resistance (Wayner et al., 2001) as well as higher risks of MI as an independent risk factor ( Pischon et al., 2004, Nakayama et al.,2004).

Accumulated evidences have revealed closely correlations between aging in women and metabolic disorders as well as related cardiovascular diseases. Post menopause women (PMW) are more apt to visceral adipodropsy because of genetic as well as hormone milieu changes (Poehlman , Toth , &Gardner , 1995; Misso et al, 2005). Epidemiologic studies have revealed that prevalence of metabolic syndrome reaches to the highest level in women elder than 60 year-old in different ethnic group

(Reynolds , He , 2005; Vasilios et al, 2005; Gu et al, 2005 ). The same prone have also been showed in CVD morbidity and mortality ( Kannel, McGee,1979 ). Thus, identification of risks of CHD in PMW by using proper criteria is virtually of crucial importance for earlier intervention.

The aim of this study was to compare the capacity of different criteria of MetS to predict risks of CHD and their associations with changes of adipocytokines in elderly post menopause women.

2. Methods

All participants were recruited in a cross-sectional investigation in local communities in Chengdu, China. All subjects were postmenopausal females (no menstruation for at least 1 year), aged ≥60 yr, without histories of hormone replacement therapy (HRT) or stopped HRT for at least 2 years. A group of doctors were responsible for collecting information from them at a direct interview in the outpatient clinics. Patients with cancers of reproductive system and in any acute stage of diseases were excluded. This study was approved by university ethic committee of Sichuan University.

Histories and related medications of CHD, type 2 diabetes mellitus, dyslipidemia, and hypertension were confirmed by a careful inquiring of the past history diagnosed.

Systolic and diastolic blood pressures (BP) were measured after resting for at least 20 minutes at a sitting position with standard up-standing mercury sphygmomanometer. Body weight, body height, waist circumferences (WC) and hip circumferences were carefully measured with the participants in light clothes and without shoes.

After an overnight fasting for 8-12 hours, blood samples were collected from each individual via venipuncture. Serums were separated by centrifuge and then stored in -20°C until analysis. Serum fasting glucose (FBG), total triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC) were measured by standardized hospital laboratory procedure.

Insulin sensitivity was estimated by calculating homeostasis model assessment (HOMA-IR) score (Matthews DR, 1985) with the following formula: fasting serum insulin × fasting serum glucose /22.5.

Serum adipocytokines (TNF alpha, IL-6, adiponectin) were measured by Quantifile ELISA kits (R&D systems, Minneapolis, MN) according to the manual.

Metabolic Syndrome was defined by following criteria:

NCEP- ATPIII definition:

At least 3 of the following abnormalities:

FBG≥110 mg/dL or taking medication for diabetes,

Abdominal obesity: WC >102cm in men or >88 cm in women

TG≥150 mg/dL, or HDL-C <40 mg/dL in men, <50 mg/dL in women,

BP≥130 or ≥85 mm Hg or previous diagnosed hypertension.

IDF definition:

Central obesity (for Chinese women, waist circumferences ≥80 cm) plus any two of the following

TG ≥150 mg/dL (1.7 mmol/L) or HDL-c<40 mg/dL (1.03 mmol/L) in men<50 mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality;

BP ≥130 mmHg / ≥85 mmHg or treatment of previously diagnosed hypertension;

FBG≥100 mg/dL (5.6 mmol/L) or previously diagnosed diabetes.

CDS definition:

At least 3 of following abnormalities

(1) Body mass index (BMI ) ≥25 kg/m2;

(2) BP≥140/90 mmHg or under antihypertensive medication;

(3) TG≥1.7 mmol/L or HDL-C <0.91 mmol/L in males and <1.0 mmol/L in females;

(4) FBG level ≥6.1 mmol/L or under antidiabetic medication.

JPN definition:

Accumulated visceral adipose tissue (waist circumference≥90cm for women and ≥85 for men)

plus at least 2 of the following metabolic abnormalities:

(1) TG≥150mg/dl and or HDL-C≤40mg/dl;

(2) Systolic BP ≥130 and or diastolic BP≥85mmHg;

(3) FBG≥110mg/dl.

Under medications for the metabolic abnormalities mentioned above should also be included.

3. Statistical analysis

All data were expressed as mean±SD. Statistical analyses were performed by using Statistic Package for Social Science (SPSS, for windows, version 12, SPSS Inc, Chicago, Ill). TNA alpha, IL-6, and adiponectin data were logarithmized when analysis. Differences among groups were analyzed with one way ANOVA and post hoc analysis. Pearson's correlation coefficients were applied for relationships between parameters. The level of significance was set as P<0.05.

4. Results

The baseline data of participants were listed in table1. The mean age was 66.77±5.09 yrs, and mean years after menopause was 18.22±7.41 yrs. Compared with data reported, the mean levels of BMI, WC, systolic BP, diastolic BP, and TG were higher than average levels of women in south China (GU D F et al, 2005). The prevalence of MetS diagnosed by IDF, NCEP ATPIII, CDS and JPN criteria were 37.34%, 27.31%, 23.29%, and 13.65%, respectively. IDF-MetS had the highest prevalence, whereas JPN-MetS had the lowest one. Each MetS group had significant higher levels of parameters related to the components of MetS than the non-MetS group defined by the same definition, except a lower HDLC level (p<0.05) (data not shown here). There were no significant differences of parameters related to metabolic disorders among different MetS groups, except a higher WC in JPN-MetS group (As showed in table2). CDS MetS group had the highest levels of BMI, glucose, TG, and SBP; JPN MetS group had the highest levels of insulin, HOMA-IR, LDLC, waist and hip circumferences, and lowest levels of HDLC; whereas IDF MetS group had the lowest levels of insulin, HOMA-IR, TG,TC,BMI, and SBP, comparatively. No significant differences were revealed among non-MetS groups defined by different criteria (data not shown here).

To evaluate correlations of different criteria of MetS with CHD and DM, prevalence of diagnosed CHD and DM related to different MetS groups were analyzed (As showed in table 3A). And odds ratios for DM and CHD were calculated (results showed in table 3B). JNP-MetS group and CDS-MetS group had comparatively higher prevalence and ORs for CHD than other two groups. More than half of the CDS and NCEP-ATPIII defined individuals had established diagnosis of DM.

Although no significant changes of adipocytokines were found among different MetS groups, CDS MetS group tended to have the lowest levels of adiponectin, whereas JPN MetS group tended to have the highest levels of TNF alpha and IL-6. Prevalence of MetS defined by different criteria in the highest and lowest quartile of adiponectin were different (data shown in table 4).

5. Discussion

Our investigation revealed differences of prevalence of MetS defined by different criteria. The reasons should be the underlying principles and cutoff points of different definitions.

NCEP ATPIII definition for metabolic syndrome is the most widely used one, because of its convenience for clinical utilization. Identified by NCEP ATPIII criteria, prevalence of MetS in our study was 26.2%. It is in consistency with other large scale investigations (Gu DF et al, 2005). This group appeared to have higher TG, lower WC and TC than their Caucasians counterparts (Tankó, L. B. et al, 2005). A generally lower level of adiponectin was also noticed. We consider these as characteristics of MetS in Chinese PMW.

Comparing with NCEP ATPIII, IDF definition of MetS gives more weight to central obesity and lowers the cutoff point of waist circumference to 80cm (for Chinese women) and fasting glucose level to 5.6mmol/L, according to the suggestions of American Diabetes Society. It defined more MetS, to the level of 37.65%, and thus seemed to be more sensitive. This is in consistency with reports from other ethnic groups (Athyros VG, et al, 2005; Earl S.F, 2005). Most of those parameters related to metabolic disorders in MetS were revealed lower in this group than in other groups, except a higher HDLC.

CDS definition of MetS seems to be a modification and combination of both WHO and NECP-ATPIII definition by choosing a comparatively higher cutoff point for hypertension and selecting BMI as a parameter for central obesity. Prevalence of MetS defined by CDS was much lower than by IDF, but similar to that defined by NCEP ATPIII. Given that the similarities between NCEP ATPIII and CDS definitions, it may mean that either BMI>25 or WC>88 identify the same in terms of visceral adipodropsy.

Like IDF definition, the JPN definition also takes central obesity as a precondition of diagnosis, with higher cutoff points of WC, which is based on the visceral fat area exceeding 100cm2 in Japanese women ( Matuzawa et al., 2005). Considering of ethnic identity and similarities in lifestyle, we applied JPN definition designed for Japanese women to our studied Chinese women. To our surprise, a sharply decrease of diagnosed MetS was revealed. Since the average WC of women in south China is only 75.6 cm as reported (Gu D F et al 2005), the cutoff points of 90cm of WC ruled out many cases whom had already had more than one metabolic disorders, and were certified to other criteria of MetS.

The dramatic change of prevalence of MetS diagnosed by different criteria in the same population give rises to an important

question: who should be treated from now? Since the final aim to define MetS is to identify individuals at high risks of CVD to whom earlier interventions are necessary, assessment of correlations of each definition with CVD and DM may help answer the previous question.

As reported in our results, NECP ATPIII definition seemed to correlate the best with DM, whereas JPN-MetS group seemed to correlated better with CHD. In MetS groups with higher CHD prevalence, like JPN-MetS group and CDS-MetS group, there were trends to have older ages, longer years after menopause, higher levels of TG, BMI, and systolic BP, although no statistical significances were revealed. We also noticed that although JPN-MetS group had the highest CHD prevalence, the prevalence of DM was the lowest and so were the levels of glucose. It also had the highest levels of waist circumferences and HOMA-IR index among the four groups. These give us such an impression that not levels of glucose but the underline basis of central obesity plays more important roles.

Adipocytokines may be the key factors link visceral adipose accumulation and atherosclerotic diseases, by playing harmful (eg.TNFalpha, IL-6) or protective (eg. adiponectin) roles. In our study, adiponectin levels were revealed to be significant higher in MetS groups than in normal groups. No significant differences were revealed between PMW with MetS and PMW with metabolic disorders but did not reach to the criteria of MetS. JPN-MetS group had the highest levels of both TNFalpha and IL-6. But we failed to reveal related lowest levels of adiponectin in this group. CDS-MetS group had the lowest levels of adiponectin. Multi-variants linear regression analysis revealed a significantly positive correspondence between TG and adiponectin, and a significantly negative correlation between HDLC and adiponectin (data not showed). TC and LDLC were revealed to significantly directly related to TNF alpha and IL-6 (data not showed). No significant correlations between adipocytokines and WC or BMI were figured out in our study. This may reflex the complication of this multiple metabolic disorder. Quartile analysis of adiponectin revealed, among all those PMW within the lowest quartile level of adiponectin, prevalence of MetS defined by CDS was the highest; while in the highest quartile, prevalence of MetS defined by JPN was the lowest (as showed in Table 4).

In San Antonio Heart Study, the differences between WHO and NCEP ATPIII criteria in predicting all-courses cardiovascular mortality were revealed (Hunt et al., 2004). Differences among different criteria in relation to confirmed CHD were revealed in our study. Our results may be limited by a comparatively small scale and the limitations of a cross-sectional study. Since this is just a primary report of an on-going multi-center, prospective study, we are looking forward to further results.

In conclusion: IDF definition for MetS is the most sensitive one to metabolic disorders, whereas JPN and CDS definitions correlate better with CHD and changes of adipocytokines. The supplementation of different dcriteria with adipocytokines may give more meanings to the definition of metabolic syndrome.

Reference

1. Alwan A, King H (ed): Report of a World Health Organization consultation. Definition, diagnosis and classification of diabetes mellitus. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance .Geneva, 1-59, 1999

1.Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP: The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin. 21(8):1157-9, 2005

1.Expert Panel on Metabolic Syndrome of Chinese Diabetes Society. Recommendations on Metabolic Syndrome of Chinese Diabetes Society (Chinese). Chin J Diab 12:156–61. 2004

1.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001

1.Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes care 28: 2745-2749, 2005

1.Goldstein BJ, Scalia R: Adiponectin: A novel adipokine linking adipocytes and vascular function  J Clin Endocrinol Metab.89(6):2563-8, 2004

1.Gu DF, Reynolds K, Wu XG, Chen J, Duan XF, Reynolds RF, Whelton PK, He J,   for the InterASIA Collaborative Group: Prevalence of the metabolic syndrome and overweight among adults in China. The lancet 365: 1398-405, 2005

1.Hunt KL, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program Versus World Health

Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study Circulation 110: 1251-1257, 2004

1.Hunt KL, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study Circulation 110: 1251-1257, 2004

1.International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Available from http:// www.idf.org/webdata/docs/Metabolicsyndrome-definition.pdf. Accessed 2 september 2005

1.Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study.JAMA 241:2035-2038, 1979

1.Lihn SA, Pedersen SB and Richelsen B: Adiponectin: action, regulation and association
to insulin sensitivity. Obesity reviews 6: 13-21, 2005

1.Matsuzawa Y: Metabolic Syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Int Med 94: 188-203, 2005

1.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 7: 412–419, 1985

1. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC, Simpson ER, Davis SR : Differential expression of factors involved in fat metabolism with age and the menopause transition Maturitas 51:299–306, 2005

1. Nakayama Y, Shimada K, Fukada Y, Ehara S, Hirose S, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J:Implications of plasma concentrations of adiponectin in patients with coronary artery diseases. Heart 90: 528-533, 2004

1.Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737, 2004

1.Poehlman ET, Toth MJ, Gardner AW: Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med123:673–5, 1995

1. Reynolds K, He J : Epidemiology of the metabolic syndrome Am J Med Sci 330(6): 273-279, 2005

1.Tankó, LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C: Enlarged Waist Combined With Elevated Triglycerides Is a Strong Predictor of Accelerated Atherogenesis and Related Cardiovascular Mortality in Postmenopausal Women Circulation 111:1183-1890, 2005

1.Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930-5, 2001

1.Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 112: 3066-3072, 2005

Table 1 Baseline data of PMW

| | | | |
|---|---|---|---|
| Age(years) | 66.77±5.09 | BMI(kg/m2) | 23.24±3.13 |
| Age at menopause(years) | 47.97±5.79 | WC (cm) | 80.07±14.94 |
| years after menopause(years) | 18.22±7.41 | hip circumference(cm) | 94.05±14.92 |
| Glucose(mmol/L) | 5.48±1.81 | systolic Bp(mmHg) | 132.16±18.44 |
| insulin(uU/ml) | 8.85±16.61 | diastolic Bp(mmHg) | 78.61±10.29 |
| TG(mmol/L) | 2.00±1.29 | HOMA-IR | 1.64±1.49 |
| TC(mmol/L) | 5.11±1.97 | TNFalpha(pg/ml) | 2.08±1.30 |
| HDLC(mmol/L) | 1.59±0.40 | IL-6(pg/ml) | 3.09±5.03 |

| LDLC(mmol/L) | 3.09±0.81 | Adiponectin(ng/ml) | 5731.25±3201.76 |

MetS, metabolic syndrome; TC, total cholesterol; TG, total triglyceride; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; BMI, body mass index; WC, waist circumference; BP, blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; TNF alpha, tumor necrosis factor alpha; IL-6, interleukin 6; PMW, post menopause women.

Table 2. Comparison of parameters among different MetS groups

| | NCEPATPIII MetS | IDF MetS | CDS MetS | JAP MetS |
|---|---|---|---|---|
| age(years) | 67.81±4.75 | 67.68±4.57 | 68.05±4.64 | 68.09±5.02 |
| age at menopause(years) | 46.91±7.70 | 46.84±6.7 | 47.19±7.03 | 45.53±9.65 |
| years after menopause(years) | 19.93±7.52 | 19.81±7.21 | 19.89±6.39 | 20.50±8.55 |
| glucose(mmol/L) | 6.34±1.98 | 6.17±2.12 | 6.50±2.01 | 6.04±1.89 |
| Insulin(uU/mL) | 13.66±28.71 | 12.59±25.33 | 16.00±31.46 | 16.7±39.29 |
| HOMA-IR | 3.97±9.28 | 3.49±8.08 | 4.62±10.02 | 4.99±12.77 |
| TG(mmol/L) | 2.75±1.56 | 2.55±1.58 | 2.84±1.82 | 2.70±1.51 |
| TC(mmol/L) | 5.05±1.09 | 5.07±0.87 | 5.08±1.12 | 5.02±1.10 |
| HDLC(mmol/L) | 1.428±0.33 | 1.50±.36 | 1.45±.322 | 1.39±0.36 |
| LDLC(mmol/L) | 2.99±0.87 | 2.98±0.83 | 2.97±0.92 | 3.00±0.92 |
| BMI(kg/m2) | 24.06±3.72 | 23.91±3.50 | 25.63±3.35 | 24.47±4.66 |
| Waist circ(cm) | 89.41±8.33 | 87.99±6.98 | 85.87±11.91 | 95.26±5.5* |
| hip circu(cm) | 102.38 | 100.62±6.86 | 99.13±12.31 | 107.13±6.6 |
| systoli Bp(mmHg) | 138.04±18.69 | 135.85±16.9 | 142.04±18.77 | 137.1±18.5 |
| diastol Bp(mmHg) | 79.85±11.21 | 79.58±10.17 | 81.46±10.96 | 79.58±10.9 |
| TNFalpha(pg/ml) | 1.89±1.16 | 1.90±0.96 | 1.81±0.97 | 2.01±1.23 |
| IL-6(pg/ml) | 2.97±4.17 | 2.86±3.91 | 2.91±3.72 | 3.12±4.07 |
| Adiponectin (ng/ml) | 5840.05±3238.94 | 6274.77±3463.60 | 4887.74±2661.62 | 5899.13 ± 3953.67 |

* p<0.05

MetS, metabolic syndrome; TC, total cholesterol; TG, total triglyceride; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; BMI, body mass index; WC, waist circumference; BP, blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; TNF alpha, tumor necrosis factor alpha; IL-6, interleukin 6; PMW, post menopause women; NCEP-ATPIII,Third Report of the National Cholesterol Education Programme Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JPN, Japanese Society of Internal Medicine.

Table 3A Prevalence of CHD and DM in different MetS group

| | Prevalence of CVD | | Prevalence of DM | |
|---|---|---|---|---|
| | diagnosed | family history | diagnosed | family history |
| IDF-MS | 18.60% | 10.52% | 39.61% | 9.21% |
| NCEP-MetS | 26.20% | 4.68% | 55.70% | 6.25% |

| | | | | |
|---|---|---|---|---|
| CDS-MS | 26.90% | 5.45% | 50% | 9.09% |
| JPN-MS | 32% | 7.40% | 36% | 7.40% |

Table 3B ORs of CHD and DM in different MetS group

| | Odds Ratio of CHD | 95% CI | Odds Ratio of DM | 95% CI |
|---|---|---|---|---|
| IDF-MetS | 1.208 | 0.778-1.876 | 2.32 | 1.702-3.162 |
| NCEP ATPIII-MetS | 1.905 | 1.273-2.851 | 4.048 | 2.802-5.848 |
| CDS-MetS | 1.997 | 1.238-3.221 | 3.041 | 1.963-4.709 |
| JPN-MetS | 2.336 | 1.119-4.876 | 2.184 | 1.058-4.507 |

NCEP-ATPIII,Third Report of the National Cholesterol Education Programme Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JPN, Japanese Society of Internal Medicine; MetS, metabolic syndrome; CHD, coronary heart disease; DM, diabetes mellitus.

Table 4 Prevalence of MetS in lower and higher quartile of adiponectin

| | adiponectine (pg/ml) | Prevalence of MetS according to different criteria(%) | | | |
|---|---|---|---|---|---|
| | | IDF | NCEP ATPIII | CDS | JPN |
| lower quartile | 301.07-3309.67 | 27.3 | 24.14 | 32.25 | 19.23 |
| upper quartile | 4751.31-7730.66 | 32.3 | 34.78 | 10.81 | 10 |

NCEP-ATPIII, Third Report of the National Cholesterol Education Programme Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF, International Diabetes Federation; CDS, Chinese Diabetes Society; JPN, Japanese Society of Internal Medicine; MetS, metabolic syndrome.